English  |  正體中文  |  简体中文  |  總筆數 :2822924  
造訪人次 :  30011146    線上人數 :  1182
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"yang j c h"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 291-300 / 428 (共43頁)
<< < 25 26 27 28 29 30 31 32 33 34 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2020-07-20T05:28:00Z Weaning outcome of solid cancer patients requiring mechanical ventilation in the intensive care unit Hsiue E.H.-C.; PEI-LIN LEE; Chen Y.-H.; Wu T.-H.; Cheng C.-F.; Cheng K.-M.; Yang P.-C.; Chen H.-W.; Lin P.-Y.; Chiang D.-L.; Wu H.-D.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2020-06-30T08:09:56Z Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Kang-Yi Su;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; KANG-YI SU; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.
臺大學術典藏 2020-06-30T08:09:52Z Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Kang-Yi Su;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; KANG-YI SU; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2020-06-30T08:09:51Z Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Kang-Yi Su;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; KANG-YI SU; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2020-05-25T07:35:28Z Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations Chia-Chi Lin; Yang J.C.-H.
臺大學術典藏 2020-05-25T07:35:27Z Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC Yang J.C.-H.; Chia-Chi Lin; Medema R.H
臺大學術典藏 2020-05-25T07:35:25Z First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments Liao B.-C; Chia-Chi Lin; Yang J.C.-H.
臺大學術典藏 2020-05-25T07:35:25Z EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer Kao H.-F; Chia-Chi Lin; Yang J.C.-H.
臺大學術典藏 2020-05-25T07:35:23Z A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors Ghamande S; Chia-Chi Lin; Cho D.C; Shapiro G.I; Kwak E.L; Silverman M.H; Tseng Y; Kuo M.-W; Mach W.B; Hsu S.-C; Coleman T; Yang J.C.-H; Cheng A.-L; Ghalib M.H; Chuadhary I; Goel S.
臺大學術典藏 2020-05-25T07:35:22Z First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial Chia-Chi Lin; Kim D.-W; Tsai C.-M; Barraclough H; Altug S; Orlando M; Park K.; Srimuninnimit V; Ahn M.-J; Mok T; Kang J.H; Yang J.C.-H

顯示項目 291-300 / 428 (共43頁)
<< < 25 26 27 28 29 30 31 32 33 34 > >>
每頁顯示[10|25|50]項目